skip to Main Content
How Rescheduling Could Have Changed Cannabis Marketing

The DEA schedules substances, chemicals, and drugs into 5 classified categories. Between Schedule 1 to 5, the level of potential for abuse gets more likely as the number goes down; so Schedule 1 is listed as the most dangerous for the public and Schedule 5 the least. A Schedule 1 drug has been identified by the government as a substance with no potential for medicinal use and a high potential for abuse. Aside from cannabis, Schedule I also includes ecstasy, peyote, and heroin. This DEA scheduling federally makes cannabis highly illegal to carry without the proper permits and bars any scientific research on the medicinal value of the plant.

The DEA has been pushing back their announcement on rescheduling cannabis (to Schedule 2) for the last couple of months. Last week, they announced that cannabis would remain Schedule 1 which has equally angered and saddened the cannabis community. Not only does this continue the war on patients that has been raging across the country, but the negative effects of federal restrictions are more severe than cocaine and oxycodone with every aspect of the plant—from research to marketing.

One of the biggest problems that cannabis has faced is a lack of scientific research. Being classified as Schedule I, any relevant scientific research outside of cannabis that comes from a sterile government garden is carried out by only a few government approved scientists. Real scientific research feeds an educational marketing platform for the industry. The ability to prove that the plant has medicinal value and move past a Schedule I classification is being blocked by that same classification. If and when the feds finally reschedule cannabis, we will be able to partake in valuable research that will only fuel marketing efforts.

There would be a bounty of research to fuel new content that will bring in an entirely unaccessed target demographic. Education-based platforms are the only way to ensure that no target client is left out of a marketing campaign. Currently, cannabis education is just conjecture or experiential. With real and hard data proving the medicinal value of cannabis, the entire industry could change.

Celeste MirandaCeleste Miranda

Celeste Miranda

Dedicated to what she does and successful in her savvy business-minded ventures, Celeste Miranda is an entrepreneur, author, founder and CEO of Miranda Marketing Labs and The Cannabis Marketing Lab. Undertaking the critical challenges of marketing an emerging industry, Miranda opened a specialized division focused on providing businesses with innovative and affordable marketing strategies. Since then, The Cannabis Marketing Lab has become a highly regarded organization in Cannabis related ventures. Comprised of a 16 person team, Celeste’s staff has years of experience and expertise in a myriad of areas such as Social Media, Search Engine Optimization, Graphic & Web Design, Creative Content Production, Advertising, PR and much more. Celeste can be reached at [email protected]

This Post Has 0 Comments

Leave a Reply

Your email address will not be published.

Recent Stories

NY’s medical marijuana patients frustrated as home-grow rules remain elusive

As the gears of the state’s rule-making process grind slowly forward, frustration and impatience best describe the feelings of New Yorkers who rely on cannabis as medicine. While the Office of Cannabis Management continues to assess the latest round of public comments on proposed rules governing personal cultivation by medical patients, a trio of such patients recently offered their experiences…

Bi-Annual Cannabis Event MJ Unpacked Announces the Debut of the MJU Venture Summit

PRESS RELEASE The event will be exclusively available to venture fund managers, family office executives and UHNW individuals, featuring speakers from leaders in the cannabis industry Las Vegas, August 11, 2022 – Recently dubbed the cannabis industry’s most inventive conference, MJ Unpacked announced the launch of the MJU Venture Summit to be held on Wednesday,…

Pot legalization measure will appear on November ballot in North Dakota

A measure to legalize recreational marijuana for adults will appear on the Nov. 8 ballot in North Dakota after clearing a final hurdle. Secretary of State Al Jaeger announced on Monday, Aug. 15, that his office validated more than 23,000 signed petitions turned in by the pro-legalization sponsoring group — well over the 15,582 signature…

How Cannabis Companies Can Avoid Lawsuits and Scrutiny with Accurate Lab Testing

By Roger Brown The enduring federal cannabis ban means cannabis companies have no national testing rules, standardization, or guidelines to follow. To make matters worse, states lack oversight mechanisms to check label accuracy and weed out bad actors efficiently. These compliance gaps, combined with the market’s misguided focus on selling unrealistically and inaccurately “high-THC strains.”…

More Categories

Back To Top
×Close search
Search